Analysis of tumor burden showed that in EGFR mice, osimertinib efficiently controlled EGFR tumor growth (Figure 3A,B), with a three-fold decrease in the percentage of tumor cells (52% in vehicle-treated and 17% in osimertinib-treated mice) (Figure 3B). The gene discussed is EGFR; the disease is neoplasm.